Novavax to Participate in Upcoming Investor Conferences
Novavax (NASDAQ: NVAX) has announced its participation in two major upcoming investor conferences in June 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Novavax (NASDAQ: NVAX) has announced its participation in two major upcoming investor conferences in June 2025. The company will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025, from 2:00-2:30 PM ET in New York. Additionally, Novavax will deliver a presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on June 11, 2025, from 2:00-2:35 PM ET in Miami Beach.
Both events will be webcasted and available on Novavax's investor relations website at ir.novavax.com, with replays accessible for 30 days following the events.
Details
News Market Reaction – NVAX
The recorded move for NVAX in the trading session of this news was +3.90%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Jefferies Global Healthcare Conference: | |
Fireside Chat | |
Date: | Wednesday, June 4, 2025 |
Time: | 2:00 – 2:30 p.m. Eastern Time (ET) |
Location: | |
Goldman Sachs 46th Annual Global Healthcare Conference: | |
Presentation | |
Date: | Wednesday, June 11, 2025 |
Time: | 2:00 – 2:35 p.m. ET |
Location: | |
A webcast of the fireside chat and presentation will be available on the Events & Presentations page of the Company's website at ir.novavax.com. A replay of the webcasts will be available for 30 days.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M® adjuvant. The Company's growth strategy seeks to optimize its existing partnerships and expand access to its proven technology platform via research and development innovation, organic portfolio expansion in infectious disease and beyond, and forging new partnerships and collaborations with other companies. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Luis Sanay, CFA
240-268-2022
ir@novavax.com
Media
Giovanna Chandler
202-709-5563
media@novavax.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-upcoming-investor-conferences-302467664.html
SOURCE Novavax, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.